HC Wainwright Increases Liquidia (NASDAQ:LQDA) Price Target to $35.00

Liquidia (NASDAQ:LQDA - Free Report) had its target price boosted by HC Wainwright from $29.00 to $35.00 in a report published on Wednesday morning,Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Liquidia's Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.26) EPS, FY2025 earnings at ($1.46) EPS, FY2026 earnings at ($0.53) EPS, FY2027 earnings at $0.07 EPS, FY2028 earnings at $0.48 EPS and FY2029 earnings at $1.44 EPS.

Several other research analysts have also issued reports on the company. Needham & Company LLC reiterated a "buy" rating and issued a $25.00 price target on shares of Liquidia in a report on Wednesday, May 21st. Scotiabank reiterated an "outperform" rating on shares of Liquidia in a report on Monday, May 5th. Oppenheimer set a $13.00 price target on Liquidia and gave the stock an "underperform" rating in a report on Monday, May 19th. Raymond James increased their price target on Liquidia from $27.00 to $29.00 and gave the stock a "strong-buy" rating in a report on Friday, May 9th. Finally, Wall Street Zen upgraded Liquidia from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $26.67.

Liquidia Trading Up 0.2%

NASDAQ LQDA traded up $0.03 during trading hours on Wednesday, hitting $15.03. 1,879,582 shares of the company's stock were exchanged, compared to its average volume of 1,088,318. The stock has a 50-day simple moving average of $14.71 and a 200 day simple moving average of $13.72. Liquidia has a 1-year low of $8.26 and a 1-year high of $19.41. The firm has a market cap of $1.28 billion, a price-to-earnings ratio of -9.22 and a beta of 0.24.

Liquidia (NASDAQ:LQDA - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.03). Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.38%. The business had revenue of $3.12 million for the quarter, compared to analyst estimates of $3.23 million. On average, sell-side analysts anticipate that Liquidia will post -1.51 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Rajeev Saggar sold 2,450 shares of the firm's stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $13.67, for a total value of $33,491.50. Following the transaction, the insider now owns 263,152 shares in the company, valued at $3,597,287.84. This trade represents a 0.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Roger Jeffs sold 14,130 shares of the firm's stock in a transaction that occurred on Monday, April 14th. The shares were sold at an average price of $13.57, for a total value of $191,744.10. Following the completion of the transaction, the chief executive officer now owns 1,006,420 shares in the company, valued at $13,657,119.40. This represents a 1.38% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 33,138 shares of company stock worth $450,233 over the last 90 days. 26.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Liquidia

Institutional investors and hedge funds have recently modified their holdings of the business. Hurley Capital LLC purchased a new stake in shares of Liquidia during the first quarter valued at approximately $32,000. GAMMA Investing LLC increased its position in shares of Liquidia by 65.6% during the first quarter. GAMMA Investing LLC now owns 2,961 shares of the company's stock valued at $44,000 after acquiring an additional 1,173 shares during the last quarter. Steward Partners Investment Advisory LLC purchased a new stake in shares of Liquidia during the fourth quarter valued at approximately $59,000. Summit Investment Advisors Inc. increased its position in shares of Liquidia by 35.0% during the fourth quarter. Summit Investment Advisors Inc. now owns 6,632 shares of the company's stock valued at $78,000 after acquiring an additional 1,719 shares during the last quarter. Finally, Quarry LP purchased a new stake in shares of Liquidia during the first quarter valued at approximately $79,000. 64.54% of the stock is owned by hedge funds and other institutional investors.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).